In Vivo Preclinical Consulting

Animal studies should be designed around a translational hypothesis, not simply selected from a list of available models. Boveevo provides scientific consulting for preclinical programmes, helping clients evaluate disease-model relevance, therapeutic mechanism, species selection, dosing strategy, study endpoints, PK/PD requirements, and biomarker plans before committing to an in vivo study.

We connect clients with qualified GLP and preclinical laboratories across India, selected according to the scientific requirements of the programme. Through this network, we can access specialized regulated toxicology, oncology, metabolic, inflammatory, autoimmune, neuroscience, cardiovascular and other disease models, along with pathology, imaging, pharmacology, specialized species and NHP capabilities.

Our role is to build the complete evidence chain—from the in vitro mechanism and target biology, to the in vivo hypothesis, and ultimately to the translational endpoint. By aligning model selection, study design, pharmacology and biomarker strategy from the outset, we help ensure that animal studies generate meaningful, decision-ready data that genuinely advances the development programme.